×

Warning

JUser: :_load: Unable to load user with ID: 151
JUser: :_load: Unable to load user with ID: 291
JUser: :_load: Unable to load user with ID: 64

Monday, 31 March 2014 22:18

De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection

By 
Rate this item
(0 votes)

Anti-endothelial cell antibodies (AECAs) are thought to be involved in the development of renal allograft rejection. To explore this further, we determine whether AECAs play a role both in predicting the incidence of allograft rejection and long-term outcomes by analysis of serum samples from 226 renal allograft recipients for AECAs pre- and post-transplant. Surprisingly, the presence of pre-existing AECAs was not associated with either an increased risk of rejection or a detrimental impact on recipient/graft survival.

Subsequent de novo AECAs, however, were associated with a significantly increased risk of early acute rejection. Moreover, these rejections tended to be more severe with a significantly increased incidence of both steroid-resistant and multiple episodes of acute rejection. The acute rejections associated with de novo AECAs did not correlate with C4d deposition at the time of renal biopsy, but did demonstrate an association with the presence of glomerulitis and peritubular capillary inflammation. Significantly more patients with de novo AECAs developed graft dysfunction. Thus, our prospective study suggests the emergence of de novo AECAs is associated with transplant rejection that may lead to allograft dysfunction.

 

 

Authors: Anja Reutzel-Selke, Johann Pratschke, Paulo N Martins, Christian Denecke, Anke Jurisch, Katja Kotsch, Andreas Pascher, Peter Neuhaus and Stefan G Tullius

Reference: Kidney International (2008) 74, 622–630; doi:10.1038/ki.2008.208; published online 28 May 2008;

http://www.nature.com/ki/journal/v74/n5/abs/ki2008208a.html#note1

 

Additional Info

  • Language: English
  • Contains Audio: No
  • Content Type: Articles
  • Source: KI
  • Year: 2014
  • Members Only: No
Read 2119 times Last modified on Monday, 31 March 2014 23:21

Global Operations Center

Avenue des Arts 1-2
1210 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact

               

Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact